|
Delayed
Sao Paulo
18:44:54 05/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 61.20 BRL | -4.05% |
|
-7.27% | -13.69% |
| 10-02 | Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870, Maintains Buy Rating | MT |
| 10-02 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 73.41B 366B 65.49B 61.02B 55.53B 105B 7,070B 105B 737B 287B 3,609B 276B 270B 11,599B | P/E 2026 * |
16.8x | P/E 2027 * | 14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 65.99B 329B 58.87B 54.85B 49.91B 93.99B 6,355B 94.69B 663B 258B 3,244B 248B 242B 10,426B | EV / Sales 2026 * |
3.88x | EV / Sales 2027 * | 3.41x |
| Free-Float |
71.06% | Yield 2026 * |
0.53% | Yield 2027 * | 0.6% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -4.05% | ||
| 1 week | -7.27% | ||
| Current month | -6.49% | ||
| 1 month | -13.08% | ||
| 3 months | +9.93% | ||
| 6 months | -6.34% | ||
| Current year | -13.69% |
| 1 week | 60.22 |  | 65.45 |
| 1 month | 60.22 | | 70.6 |
| Current year | 50 | | 73.16 |
| 1 year | 49.65 | | 73.33 |
| 3 years | 44.82 | | 111.72 |
| 5 years | 44.82 | | 111.72 |
| 10 years | 18.16 | | 111.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 31/12/2000 | |
| Chief Executive Officer | 73 | 07/01/1988 | |
| Director of Finance/CFO | 55 | 04/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 08/06/2023 | |
Joseph Goldstein
BRD | Director/Board Member | 85 | 31/05/1991 |
George Sing
BRD | Director/Board Member | 76 | 07/01/1988 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.05% | -7.27% | - | - | 73.41B | |
| +0.63% | -2.97% | +36.04% | +112.31% | 1,019B | |
| -1.15% | -6.77% | +34.74% | +61.34% | 617B | |
| +0.29% | -1.13% | +14.37% | +78.54% | 464B | |
| -3.04% | -5.75% | +57.82% | +35.28% | 356B | |
| +0.93% | -1.83% | +20.98% | +41.43% | 333B | |
| +0.12% | -4.05% | +10.09% | +33.53% | 267B | |
| -0.89% | -5.83% | -7.56% | +7.91% | 244B | |
| -0.08% | -3.67% | +36.94% | +51.94% | 218B | |
| -0.46% | -5.39% | +26.79% | +92.78% | 179B | |
| Average | -0.83% | -3.54% | +25.58% | +57.23% | 410.8B | |
| Weighted average by Cap. | -0.39% | -3.54% | +28.70% | +68.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.01B 84.88B 15.18B 14.14B 12.87B 24.23B 1,639B 24.41B 171B 66.48B 836B 63.87B 62.49B 2,688B | 18.51B 92.35B 16.51B 15.39B 14B 26.37B 1,783B 26.56B 186B 72.33B 910B 69.49B 67.99B 2,925B |
| Net income | 4.95B 24.7B 4.42B 4.12B 3.75B 7.05B 477B 7.11B 49.73B 19.35B 243B 18.59B 18.19B 782B | 5.49B 27.37B 4.89B 4.56B 4.15B 7.81B 528B 7.87B 55.09B 21.43B 270B 20.59B 20.15B 867B |
| Net Debt | -7.42B -37.03B -6.62B -6.17B -5.61B -10.57B -715B -10.65B -74.54B -29B -365B -27.86B -27.26B -1,173B | -10.32B -51.46B -9.2B -8.57B -7.8B -14.69B -993B -14.8B -104B -40.31B -507B -38.72B -37.89B -1,630B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/10/26 | R$61.20 | -4.05% | 3,426 |
| 02/10/26 | R$63.78 | -1.39% | 6,817 |
| 01/10/26 | R$64.68 | -1.18% | 58 |
| 30/09/26 | R$65.45 | +0.43% | 127 |
| 29/09/26 | R$65.17 | -1.26% | 348 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
- REGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
